In this exclusive video, Edward L. Barnes, MD, MPH, from The University of North Carolina at Chapel Hill, discussed a study comparing the use of aminosalicylate monotherapy in older vs. younger patients with inflammatory bowel disease.

Barnes and colleagues collected data from the TARGET-IBD multicenter, observational cohort.

He said patients aged 65 years or older were significantly more likely than younger patients to use aminosalicylate monotherapy.

“We know that the prevalence of IBD is going to continue to increase as our aging population with Crohn’s disease and ulcerative

Full Article: